Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Date:10/30/2007

cense revenues for the third quarter of 2007 were $1.2 million, compared to $7.3 million in the prior year period. In the third quarter of 2006, royalty and license revenues were high due to $5.0 million of revenue associated with the first payment arising from the successful settlement of Gen-Probe's patent infringement claims against Bayer HealthCare (now Siemens Medical Solutions Diagnostics). Gen-Probe also earned $1.0 million of license revenue in the prior year period under a 2004 agreement with Tosoh Corporation. For the first nine months of 2007, royalty and license revenues were $14.4 million, compared to $9.2 million in the prior year period. This 57% increase resulted primarily from $10.3 million of royalty revenue that was recorded in the first quarter of 2007 associated with the second payment arising from the Bayer patent litigation.

Gross margin on product sales in the third quarter of 2007 was 67.3%, compared to 70.9% in the prior year period. This decrease resulted primarily from an unfavorable product sales mix, namely increased sales of low-margin instrumentation to clinical diagnostics and blood screening customers. For the first nine months of 2007, gross margin on product sales was 67.3%, compared to 68.2% in the prior year period.

Research and development (R&D) expenses in the third quarter of 2007 were $27.6 million, compared to $24.2 million in the prior year period, an increase of 14%. This increase, which was expected, resulted primarily from the purchase of human papillomavirus (HPV) oligonucleotides from Roche. For the first nine months of 2007, R&D expenses were $72.8 million, compared to $63.8 million in the prior year period, an increase of 14%.

Marketing and sales expenses in the third quarter of 2007 were $9.7 million, compared to $9.5 million in the prior year period, an increase of 2%. For the first nine months of 2007, marketing and sales expenses were $28.6 million, compared to $27.5 million in the prior year p
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Health Enhancement Products, Inc. (OTCQB: HEPI), a Michigan ... metabolic processes, is pleased to announce the addition of a ... Nola E. Masterson , a California -based ... 17, 2014. "We,re very pleased and honored ... Andrew Dahl , President and CEO. "She joins us ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s Flametec ... competitive in the semiconductor, clean room and medical ... product quality and productivity, according to Dwight Leatherwood, ... 1980 in Lewisville, TX, Leatherwood Plastics ... the business. Much of Leatherwood’s equipment building relies ...
(Date:9/18/2014)... 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... concurrent but separate underwritten offerings of 10,000,000 shares of ... of $2.00 per share, for expected gross proceeds of ... Convertible Preferred Stock at a price to the public ... $20 million. Each share of Series A Convertible Preferred ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... In eCTD Migration And Submissions Outsourcing And, Provides Insights Into ... ... And Europe, PHILADELPHIA and LONDON, July 17 The Scientific,business ... Regulatory Affairs Trends Survey. The survey attracted respondents,from across the globe ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... August 7, 2008., A conference call and ... for the company,s bondholders following the distribution of ... Oncology,s management,team will discuss the financial results. Further ...
... TORONTO, July 16 /PRNewswire/ - Eugene Melnyk and ... see a number of incomplete or,inaccurate statements in ... "The hallmark of this proxy contest to date ... see the Board and management using the,same tactics," ...
Cached Biology Technology:The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 2The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 3
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... of researchers from McGill University and the Quebec ... polyethylene ,microbeads, Canadian Journal of Fisheries and ... from cosmetics, household cleansers, or industrial cleansers, to ... to their small size and buoyancy, they may ... are a global contaminant in the world,s oceans, ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... Troy, N.Y. The purification of drug components is ... particularly true of drugs that utilize proteins, which are ... Scientists within the Center for Biotechnology and Interdisciplinary Studies ... resonance (NMR) to understand and improve an important protein ...
... to anchor teeth back in the jaw using stem cells ... the first time by researchers at the University of Illinois ... advance in the battle against gum disease, a serious infection ... U.S. adults suffer from gum disease, according to the National ...
... recent human trials for a promising new class of ... without shutting down the immune system, some of the ... In response, an interdisciplinary team of Florida State ... genetic screening method that can identify the drug-resistant HCV ...
Cached Biology News:Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3Technique to reattach teeth using stem cells developed at UIC 2Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Catch and Release® v2.0 Reversible Immunoprecipitation System...
... Peptide-Protein Conjugation, Quantities ... Complex Peptides/Peptidomimetics, Special amino ... Structures, Peptide labeling AMC, aldehyde, ... fitting your needs, Chromogenic/Flurogenic Substrates, ...
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
Biology Products: